(NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product cabozantinib while ...

Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its ...

The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO's lead program, OK-101 focused on treating ...

Coherus BioSciences (CHRS) announced final data from its Phase 2 open label clinical trial evaluating casdozokitug, a selective and potent ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

One of the best ways to address the gap between healthcare providers and patients is by making diagnostic processes more ...

This significant downturn reflects a staggering 1-year change, with the company's stock value eroding by -84.83%. Investors have watched with concern as Omega, known for its innovative approaches in ...

Knight Therapeutics Inc. (OTCMKTS:KHTRF – Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.

EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.